21 Results for "

hepg2.2.15 cells

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "hepg2.2.15 cells" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-B1826
CAS No.: 106941-25-7
Synonyms: GS-0393; PMEA
Research Areas:  

Infection

Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16679
CAS No.: 203935-39-1
Synonyms: Helioxanthin 5-4-2
Target:  

HBV

Research Areas:  

Infection

Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.
loading...
    loading...
Cat. No.: HY-145586
CAS No.: 2200336-20-3
Purity:  99.95%
Synonyms: ZSP1273
Research Areas:  

Infection

Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
loading...
    loading...
Cat. No.: HY-157993
CAS No.: 2246696-89-7
Purity:  98.50%
Target:  

HBV

Research Areas:  

Infection

SAG-524 is a potent oral small molecule HBV viral replication inhibitor. SAG-524 decreased HBV-DNA and HbsAg levels in supernatant of HepG2.2.15 cells, IC50 0.92 and 1.4 nM, respectively .
loading...
    loading...
Cat. No.: HY-147255
CAS No.: 2137847-19-7
Purity:  98.40%
Synonyms: ZM-H1505R
Target:  

HBV

Research Areas:  

Infection

Canocapavir (ZM-H1505R) is an orally active HBV core protein-targeting antiviral agent. Canocapavir binds to the hydrophobic pocket at the dimer-dimer interface of HBV core protein (HBc), stimulating intracellular accumulation of nonfunctional HBV capsids, disrupting viral replication. Canocapavir interferes with the interaction between HBc and HBV large surface protein, resulting in diminished
production of empty virionsis. Canocapavir can be used for the research of hepatitis B virus (HBV) infection .
loading...
    loading...
Cat. No.: HY-N1323
CAS No.: 1351931-30-0
Sanggenol P, a flavonoid, shows anti-HBV activity on HepG2.2.15 cell line in vitro .
loading...
    loading...
Cat. No.: HY-126970
CAS No.: 957011-15-3
Purity:  99.99%
Target:  

HBV

Research Areas:  

Infection

HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .
loading...
    loading...
Cat. No.: HY-109969
CAS No.: 1005459-82-4
Target:  

HBV

Research Areas:  

Infection

Z060228 is a capsid-targeting anti-HBV agent that inhibits HBV DNA replication in the supernatant of the HepG2.2.15 cell .
loading...
    loading...
Cat. No.: HY-119702
CAS No.: 1835652-66-8
Target:  

HBV

Research Areas:  

Infection

YZ51 is a derivative of Osalmid (HY-B2116) with stronger ribonucleotide reductase (RR) inhibitory activity and HBV replication inhibition ability than Osalmid. The IC50 of YZ51 against recombinant RR activity is 0.6 μM, and the IC50 against HepG2.2.15 cell RR activity is 23.7 μM .
loading...
    loading...
Cat. No.: HY-145052
CAS No.: 2170998-69-1
Target:  

HBV

Research Areas:  

Infection

HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.
loading...
    loading...
Cat. No.: HY-116607
CAS No.: 246872-58-2
Target:  

HBV

Research Areas:  

Infection

BAY38-7690 is a non-nucleoside inhibitor that inhibits HBV replication. BAY38-7690 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY38-7690 against HBV in stably transfected HepG2.2.15 cells is 0.15 μM .
loading...
    loading...
Cat. No.: HY-117999
CAS No.: 247037-81-6
Target:  

HBV

Research Areas:  

Infection

BAY39-5493 is a non-nucleoside inhibitor that inhibits HBV replication. BAY39-5493 inhibits viral DNA replication by preventing the formation of viral core particles (nucleocapsids). The IC50 value of BAY39-5493 against HBV in stably transfected HepG2.2.15 cells is 0.03 μM .
loading...
    loading...
Cat. No.: HY-N2882
CAS No.: 133538-77-9
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells .
loading...
    loading...
Cat. No.: HY-145586A
CAS No.: 2375241-19-1
Synonyms: ZSP1273 monohydrate
Research Areas:  

Infection

Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
loading...
    loading...
Cat. No.: HY-B1826S2
CAS No.: 1190021-70-5
Synonyms: GS-0393-d4; PMEA-d4
Adefovir-d4 is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses .
loading...
    loading...
Cat. No.: HY-116633
CAS No.: 1820763-99-2
Target:  

Endogenous Metabolite

Research Areas:  

Infection

BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .
loading...
    loading...
Cat. No.: HY-144320
CAS No.: 2270943-13-8
Target:  

HBV

Research Areas:  

Infection

HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC50 of 511 nM .
loading...
    loading...
Cat. No.: HY-162327
Research Areas:  

Infection

PROTAC PAPD5 degrader 1 is a selective PAPD5 PROTAC degrader. PROTAC PAPD5 degrader 1 induces ubiquitination and degradation of PAPD5 without causing degradation of PAPD7. PROTAC PAPD5 degrader 1 reduces Hepatitis B virus mRNA and Hepatitis B surface antigen levels in vitro. PROTAC PAPD5 degrader 1 inhibits both Hepatitis A virus and Hepatitis B virus. PROTAC PAPD5 degrader 1 can be used for research on Hepatitis A virus infection and Hepatitis B virus infection .
loading...
    loading...
Cat. No.: HY-126970R
CAS No.: 957011-15-3
Target:  

HBV

Research Areas:  

Infection

HBF-0259 (Standard) is the analytical standard of HBF-0259. This product is intended for research and analytical applications. HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis .
loading...
    loading...
Cat. No.: HY-183576
Target:  

HBV

Research Areas:  

Infection Neurological Disease

HBsAg-IN-1 is an orally active, highly liver-selective inhibitor of HBsAg production, with an EC50 of 0.63 nM. HBsAg-IN-1 shows no neurite growth inhibitory activity. HBsAg-IN-1 can be used in studies related to hepatitis B virus (HBV) infection .
loading...
    loading...